Tissue Engineered Models of Brain Tumors and Their Applications

113

[202] T. Yu, Y. Wang, and Q. Hu et al., “The EZH2 inhibitor GSK343 sup-

presses cancer stem-like phenotypes and reverses mesenchymal transi-

tion in glioma cells,” Oncotarget, vol. 8, no. 58, pp. 98348–98539, 2017.

[203] M. A. Hermida, J. D. Kumar, and D. Schwarz et al., “Three dimensional

in vitro models of cancer: bioprinting multilineage glioblastoma models,”

Advances in Biological Regulation, vol. 75, p. 100658, 2020.

[204] J. P. Straehla, C. Hajal, and H. C. Safford, “A predictive microflu-

idic model of human glioblastoma to assess trafficking of blood–brain

barrier-penetrant nanoparticles,” Proceedings of the National Academy

of Sciences, vol. 119, no. 23, p. e2118697119, 2022.

[205] Y. Fan, D. T. Nguyen, and Y. Akay et al., “Engineering a brain can-

cer chip for high-throughput drug screening,” Scientific Reports, vol. 6,

no. 1, p. 25062, 2016.

[206] M. Ratliff, H. Kim, and H. Qi et al., “Patient-derived tumor organoids

for guidance of personalized drug therapies in recurrent glioblastoma,”

International Journal of Molecular Sciences, vol. 23, no. 12, p. 6572,

2022.

[207] S. Han and J. Wu, “Three-dimensional (3D) scaffolds as powerful

weapons for tumor immunotherapy,” Bioactive Materials, vol. 17,

pp. 300–319, 2022.

[208] L. Barros, M. A. Pretti, and L. Chicaybam et al., “Immunological-based

approaches for cancer therapy,” Clinics, vol. 73, p. e429s, 2018.

[209] P. Mu, S. Zhou, and T. Lv et al., “Newly developed 3D in vitro models to

study tumor–immune interaction,” Journal of Experimental & Clinical

Cancer Research, vol. 42, no. 1, p. 81, 2023.

[210] M. W. Yu and D. F. Quail, “Immunotherapy for glioblastoma: current

progress and challenges,” Frontiers in Immunology, vol. 12, p. 676301,

2021.

[211] M. Yang, I. Y. Oh, and A. Mahanty et al., “Immunotherapy for glioblas-

toma: current state, challenges, and tuture perspectives,” Cancers,

vol. 12, no. 9, 2020.

[212] X. Xu, F. Stockhammer, and M. Schmitt et al., “Cellular-based im-

munotherapies for patients with glioblastoma multiforme,” Journal of

Immunology Research, vol. 2012, p. 764213, 2012.

[213] M. Bausart, V. Préat, and A. Malfanti, “Immunotherapy for glioblas-

toma: the promise of combination strategies,” Journal of Experimental

& Clinical Cancer Research, vol. 41, no. 1, p. 35, 2022.